GENE ONLINE|News &
Opinion
Blog

2026-05-07|

QIAGEN Automates Latent TB Testing with New Workflow and AI Risk Tool for QuantiFERON

by GOAI
Share To

QIAGEN announced plans to release a new fully automated workflow and an AI-powered risk stratification tool to improve QuantiFERON latent tuberculosis (TB) testing. The new workflow will automate the entire process from sample to insight, while the AI tool will help to identify individuals at high risk of developing active TB.

The fully automated workflow is designed to streamline the QuantiFERON TB Gold Plus assay, reducing hands-on time and minimizing the risk of human error. The AI-enabled risk stratification tool will analyze patient data to predict the likelihood of TB activation, allowing for more targeted interventions and preventative care. QIAGEN expects these innovations to enhance the efficiency and accuracy of latent TB testing, ultimately contributing to better patient outcomes and public health.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
Ellomay Capital Completes Sale of Dorad Energy Holdings on May 10, 2026
2026-05-10
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
2026-05-10
Digoxin Lowers Death Risk and Heart Failure in Rheumatic Heart Disease Patients, Study Finds
2026-05-10
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
2026-05-10
India’s Pharmaceutical Growth Slows: Industry Needs New Strategies
2026-05-10
MoonLake Immunotherapeutics Concludes Pre-BLA Meeting with FDA and Reports Q1 2026 Financial Results
2026-05-10
New Method Allows Repeated Genetic Data Extraction From Living Cells Without Destruction
2026-05-10
Scroll to Top